An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.
Lin J, Liu J, Hao SG, Lan B, Zheng XB, Xiong JN, Zhang YQ, Gao X, Chen CB, Chen L, Huang YF, Luo H, Yi YT, Yi X, Lu JP, Zheng XW, Chen G, Wang XF, Chen Y.
Lin J, et al. Among authors: chen l, chen cb, chen g, chen y.
Front Immunol. 2022 Nov 23;13:1022598. doi: 10.3389/fimmu.2022.1022598. eCollection 2022.
Front Immunol. 2022.
PMID: 36505399
Free PMC article.